Cell therapy for heart attack with cardiogenic shock
Part of Heart & circulation clinical trials.
This trial tests a new kind of cell therapy made from donor cells that aims to reduce inflammation and help the heart recover after a severe heart attack. It's designed for people who are in cardiogenic shock (when the heart can't pump enough blood) despite having had emergency procedures like stents or bypass surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 79 years old.
- You had a severe heart attack and are in cardiogenic shock (low blood pressure despite medication or needing a machine to support blood pressure).
- You have signs that organs aren't getting enough blood, such as confusion, cold/clammy skin, low urine output, or high blood lactate.
- You have already had an emergency procedure to open blocked arteries (PCI or CABG).
- You are not pregnant, have no active infections, no history of cancer, and no autoimmune disease requiring treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new blood-filtering device called Efferon CT for people with cardiogenic shock after a heart attack. The device aims to help your body recover by cleaning harmful substances from your blood, and you might join if you are diagnosed early and don't have other serious health issues.
This early-phase study tests a new type of immune cell therapy (CAR-DC) for people with advanced heart failure due to blocked arteries. It aims to see if the treatment is safe and may help improve heart function.
This trial tests a second dose of specialized immune cells (called CAR-DC) in patients with severe dilated cardiomyopathy (a weakened heart muscle) who received one dose before but saw their heart function decline back to baseline. The goal is to see if a second dose is safe and can improve heart function when the first treatment's benefits wore off.
This trial tests a new treatment called FAP iCDC for people with end-stage dilated cardiomyopathy, a type of heart muscle disease. It aims to see if this therapy is safe and helps improve heart function when standard medicines are no longer enough.
This trial tests whether injecting special heart muscle cells (made from stem cells) during a heart bypass or a heart pump surgery can help improve your heart's function. It is for people with severe heart failure who are already planning one of these surgeries.
This study tests an experimental cell therapy called MiSaver that may help heart muscle recover after a heart attack. It's for people whose hearts are weak and who cannot have usual procedures like stents or bypass surgery.
Hear when a new Cardiogenic Shock trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.